Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

INTRODUCTION: Misfolded aggregated proteins and neuroinflammation significantly contribute to amyotrophic lateral sclerosis (ALS) pathogenesis, hence representing therapeutic targets to modify disease expression. Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophag...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandrioli, Jessica, D’Amico, Roberto, Zucchi, Elisabetta, Gessani, Annalisa, Fini, Nicola, Fasano, Antonio, Caponnetto, Claudia, Chiò, Adriano, Dalla Bella, Eleonora, Lunetta, Christian, Mazzini, Letizia, Marinou, Kalliopi, Sorarù, Gianni, de Biasi, Sara, Lo Tartaro, Domenico, Pinti, Marcello, Cossarizza, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024184/
https://www.ncbi.nlm.nih.gov/pubmed/29901635
http://dx.doi.org/10.1097/MD.0000000000011119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024184/
https://www.ncbi.nlm.nih.gov/pubmed/29901635
http://dx.doi.org/10.1097/MD.0000000000011119

Ejemplares similares